# Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

> **NCT01103375** · PHASE1 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 5 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Oligodendroglioma
- Adult Diffuse Astrocytoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Oligodendroglioma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** isotretinoin
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** protein expression analysis

## Key facts

- **NCT ID:** NCT01103375
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103375, "Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01103375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*